The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
Open accessAbstract
We explored the mechanism of action of CD39 antibodies that inhibit ectoenzyme CD39 conversion of extracellular ATP (eATP) to AMP and thus potentially augment eATP–P2-mediated proinflammatory responses. Using syngeneic and humanized tumor models, we contrast the potency and mechanism of anti-CD39 mAbs with other agents targeting the adenosinergic pathway. We demonstrate the critical importance of an eATP–P2X7–ASC–NALP3-inflammasome–IL18 pathway in the antitumor activity mediated by CD39 enzyme blockade, rather than simply reducing adenosine as mechanism of action. Efficacy of anti-CD39 activity was underpinned by CD39 and P2X7 coexpression on intratumor myeloid subsets, an early signature of macrophage depletion, and active IL18 release that facilitated the significant expansion of intratumor effector T cells. More importantly, anti-CD39 facilitated infiltration into T cell–poor tumors and rescued anti–PD-1 resistance. Anti-human CD39 enhanced human T-cell proliferation and Th1 cytokine production and suppressed human B-cell lymphoma in the context of autologous Epstein–Barr virus–specific T-cell transfer. Significance: Overall, these data describe a potent and novel mechanism of action of antibodies that block mouse or human CD39, triggering an eATP–P2X7–inflammasome–IL18 axis that reduces intratumor macrophage number, enhances intratumor T-cell effector function, overcomes anti–PD-1 resistance, and potentially enhances the efficacy of adoptive T-cell transfer. This article is highlighted in the In This Issue feature, p. 1631
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms
Li, X.-Y., Das, I., Lepletier, A., Addala, V., Bald, T., Stannard, K. A., Barkauskas, D. S., Liu, J., Aguilera, A. R., Takeda, K., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98769 · Cited by 127
Self-citationRetractedSTAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
Self-citationConditional gene targeting in macrophages and granulocytes using LysMcre mice
Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R., & Förster, I. (1999) · Transgenic Research · doi:10.1023/a:1008942828960 · Cited by 2,098
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationBystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370
Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Höpner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064527 · Cited by 1,286
The P2X7 Receptor: A Key Player in IL-1 Processing and Release
Ferrari, D., Pizzirani, C., Adinolfi, E., Lemoli, R. M., Curti, A., Idzko, M., Panther, E., & Di Virgilio, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.7.3877 · Cited by 1,025
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944 · cited 1×
“DECEMBER 2019 CANCER DISCOVERY | 1755 INTRODUCTION Immune-checkpoint blockade (ICB) using antagonistic antibodies to CTLA4, PD-1, and PD-L1 has revolutionized the cancer treatment paradigm (1).”
BackgroundSelf-citationCo-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N. F., Goodall, C. P., Blair, T. C., Fox, B. A., McDermott, J. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05072-0 · Cited by 938 · cited 1×
“Recent reports also suggest that CD39 is a marker of tumor-reactive effector T-cell subsets (25, 26) and is increasingly appreciated as a regulatory marker (27).”
BackgroundAltered Cytokine Production in Mice Lacking P2X7Receptors
Solle, M., Labasi, J., Perregaux, D. G., Stam, E., Petrushova, N., Koller, B. H., Griffiths, R. J., & Gabel, C. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006781200 · Cited by 930
RNA-SeQC: RNA-seq metrics for quality control and process optimization
DeLuca, D. S., Levin, J. Z., Sivachenko, A., Fennell, T., Nazaire, M.-D., Williams, C., Reich, M., Winckler, W., & Getz, G. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts196 · Cited by 899
ATP Release Guides Neutrophil Chemotaxis via P2Y2 and A3 Receptors
Chen, Y., Corriden, R., Inoue, Y., Yip, L., Hashiguchi, N., Zinkernagel, A., Nizet, V., Insel, P. A., & Junger, W. G. (2006) · Science · doi:10.1126/science.1132559 · Cited by 858
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
Self-citationPurinergic regulation of the immune system
Cekic, C., & Linden, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.4 · Cited by 787
Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase
Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V., & Di Virgilio, F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002599 · Cited by 668
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
Landsberg, J., Kohlmeyer, J., Renn, M., Bald, T., Rogava, M., Cron, M., Fatho, M., Lennerz, V., Wölfel, T., Hölzel, M., et al. (2012) · Nature · doi:10.1038/nature11538 · Cited by 632
Self-citationEnjyoji, K., Sévigny, J., Lin, Y., Frenette, P. S., Christie, P. D., Esch, J. S. A., Imai, M., Edelberg, J. M., Rayburn, H., Lech, M., et al. (1999) · Nature Medicine · doi:10.1038/12447 · Cited by 565
Self-citationHaskó, G., Szabó, C., Németh, Z. H., Kvetan, V, Pastores, S. M., & Vizi, E. S. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.10.4634 · Cited by 536
Haskó, G., Kuhel, D. G., Chen, J.-F., Schwarzschild, M. A., Deitch, E. A., Mabley, J. G., Marton, A., & Szabó, C. (2000) · The FASEB Journal · doi:10.1096/fj.99-0508com · Cited by 512
Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
Hu, B., Ren, J., Luo, Y., Keith, B., Young, R. M., Scholler, J., Zhao, Y., & June, C. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.002 · Cited by 506
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Acquired resistance to immunotherapy and future challenges
Restifo, N. P., Smyth, M. J., & Snyder, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.2 · Cited by 467
Self-citationCD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells
Canale, F. P., Ramello, M. C., Núñez, N., Furlan, C. L. A., Bossio, S. N., Serrán, M. G., Boari, J. T., del Castillo, A., Ledesma, M., Sedlik, C., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-16-2684 · Cited by 408
The P2X7 receptor: A main player in inflammation
Adinolfi, E., Giuliani, A. L., De Marchi, E., Pegoraro, A., Orioli, E., & Di Virgilio, F. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.12.021 · Cited by 385 · cited 1×
“P2X7 is the major functional eATP receptor on immune cells and is a critical factor in NALP3 inflammasome activity (41).”
BackgroundA2A Adenosine Receptor Induction Inhibits IFN-γ Production in Murine CD4+ T Cells
Lappas, C. M., Rieger, J. M., & Linden, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.1073 · Cited by 385
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
Ohta, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00109 · Cited by 385
Sun, X., Wu, Y., Gao, W., Enjyoji, K., Csizmadia, E., Müller, C. E., Murakami, T., & Robson, S. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.007 · Cited by 279
Self-citationGlodde, N., Bald, T., van den Boorn-Konijnenberg, D., Nakamura, K., O’Donnell, J. S., Szczepanski, S., Brandes, M., Eickhoff, S., Das, I., Shridhar, N., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.09.012 · Cited by 277
Self-citationLimagne, E., Euvrard, R., Thibaudin, M., Rébé, C., Derangère, V., Chevriaux, A., Boidot, R., Végran, F., Bonnefoy, N., Vincent, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3164 · Cited by 264
Eradication of established tumors in mice by a combination antibody-based therapy
Uno, T., Takeda, K., Kojima, Y., Yoshizawa, H., Akiba, H., Mittler, R. S., Gejyo, F., Okumura, K., Yagita, H., & Smyth, M. J. (2006) · Nature Medicine · doi:10.1038/nm1405 · Cited by 257
Self-citationAutocrine Purinergic Receptor Signaling Is Essential for Macrophage Chemotaxis
Kronlage, M., Song, J., Sorokin, L., Isfort, K., Schwerdtle, T., Leipziger, J., Robaye, B., Conley, P. B., Kim, H.-C., Sargin, S., et al. (2010) · Science Signaling · doi:10.1126/scisignal.2000588 · Cited by 250
Bastid, J., Regairaz, A., Bonnefoy, N., Déjou, C., Giustiniani, J., Laheurte, C., Cochaud, S., Laprevotte, E., Funck-Brentano, E., Hemon, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0018 · Cited by 240
A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1
Ngiow, S. F., Young, A., Jacquelot, N., Yamazaki, T., Enot, D., Zitvogel, L., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1082 · Cited by 237
Self-citationSelby, M. J., Engelhardt, J. J., Johnston, R. J., Lu, L.-S., Han, M., Thudium, K., Yao, D., Quigley, M., Valle, J., Wang, C., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0161779 · Cited by 231
Self-citationSitkovsky, M. V., Hatfield, S., Abbott, R., Belikoff, B., Lukashev, D., & Ohta, A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0075 · Cited by 215
Ohta, A., Ohta, A., Madasu, M., Kini, R., Subramanian, M., Goel, N., & Sitkovsky, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901247 · Cited by 215
Regulation of the T Cell Response by CD39
Takenaka, M. C., Robson, S., & Quintana, F. J. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.009 · Cited by 207
Self-citationGu, J., Ni, X., Pan, X., Lu, H., Lu, Y., Zhao, J., Guo Zheng, S., Hippen, K. L., Wang, X., & Lu, L. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.30 · Cited by 204
ENTPD1/CD39 is a promising therapeutic target in oncology
Bastid, J., Cottalorda-Regairaz, A., Alberici, G., Bonnefoy, N., Eliaou, J.-F., & Bensussan, A. (2013) · Oncogene · doi:10.1038/onc.2012.269 · Cited by 202
Adenosine and cAMP are potent inhibitors of the NF‐κB pathway downstream of immunoreceptors
Minguet, S., Huber, M., Rosenkranz, L., Schamel, W. W. A., Reth, M., & Brummer, T. (2005) · European Journal of Immunology · doi:10.1002/eji.200425524 · Cited by 197
Teng, M. W. L., Ngiow, S. F., von Scheidt, B., McLaughlin, N., Sparwasser, T., & Smyth, M. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1681 · Cited by 192
Self-citationdel Barrio, I. M., Penski, C., Schlahsa, L., Stein, R. G., Diessner, J., Wöckel, A., Dietl, J., Lutz, M. B., Mittelbronn, M. G. A., Wischhusen, J., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0154-9 · Cited by 175
Feng, L., Sun, X., Csizmadia, E., Han, L., Shu, B., Murakami, T., Wang, X., Robson, S. C., & Wu, Y. (2011) · Neoplasia · doi:10.1593/neo.101332 · Cited by 145
Self-citationKoziak, K., Sévigny, J., Robson, S. C., et al. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614868 · Cited by 126
Self-citationTargeting A2 adenosine receptors in cancer
Allard, D., Turcotte, M., & Stagg, J. (2017) · Immunology and Cell Biology · doi:10.1038/icb.2017.8 · Cited by 122
Disordered Purinergic Signaling Inhibits Pathological Angiogenesis in Cd39/Entpd1-Null Mice
Jackson, S. W., Hoshi, T., Wu, Y., Sun, X., Enjyoji, K., Cszimadia, E., Sundberg, C., & Robson, S. C. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070190 · Cited by 113
Self-citationHai, Z., Bo, C., Kang, Y., & Li, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00727 · Cited by 112
GAM: a web-service for integrated transcriptional and metabolic network analysis
Sergushichev, A. A., Loboda, A. A., Jha, A. K., Vincent, E. E., Driggers, E. M., Jones, R. G., Pearce, E. J., & Artyomov, M. N. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw266 · Cited by 94 · cited 1×
“GSEA was performed using the “fgsea” R package (71).”
MethodThe role of NK cells and CD39 in the immunological control of tumor metastases
Zhang, H., Vijayan, D., Li, X.-Y., Robson, S. C., Geetha, N., Teng, M. W. L., & Smyth, M. J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593809 · Cited by 93
Self-citationSun, X., Han, L., Seth, P., Shu, B., Li, L., Csizmadia, E., JUNGER, W. G., Schmelzle, M., Usheva, A., Tapper, E. B., et al. (2012) · Hepatology · doi:10.1002/hep.25989 · Cited by 90
Self-citationEppell, B. A., Newell, A. M., & Brown, E. J. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.12.4141 · Cited by 80
Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies
Siu, L. L., Ivy, S. P., Dixon, E. L., Gravell, A. E., Reeves, S. A., & Rosner, G. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3079 · Cited by 75
P2 receptors in cancer progression and metastatic spreading
Virgilio, F. D., Falzoni, S., Giuliani, A. L., & Adinolfi, E. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.05.001 · Cited by 60
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity
Kashyap, A. S., Thelemann, T., Klar, R., Kallert, S. M., Festag, J., Buchi, M., Hinterwimmer, L., Schell, M., Michel, S., Jaschinski, F., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0545-9 · Cited by 60
Mouse Models of Tumor Immunotherapy
Ngiow, S. F., Loi, S., Thomas, D. M., & Smyth, M. J. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.004 · Cited by 44
Self-citationCD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.
Hayes, G. M., Cairns, B., Levashova, Z. B., Chinn, L., Perez, M., Theunissen, J.-W. F., Liao-Chan, S., Bermudez, A., Flory, M. R., Schweighofer, K. J., et al. (2015) · PubMed Central · Cited by 41
High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma
Zhang, B., Cheng, B., Li, F., Ding, J., Feng, Y., Zhuo, G., Wei, H., & Zhao, K. (2015) · Tumor Biology · doi:10.1007/s13277-015-3683-9 · Cited by 40
CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression
Bonnefoy, N., Bastid, J., Alberici, G. F., Bensussan, A., & Eliaou, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1003015 · Cited by 39
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells—Letter
Thelen, M., Lechner, A., Wennhold, K., von Bergwelt‐Baildon, M., & Schlößer, H. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0873 · Cited by 27
Schäfer, U., Machida, T., Broekman, M. J., Marcus, A. J., & Levi, R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.125328 · Cited by 21
Cited by
Detection of immunogenic cell death and its relevance for cancer therapy
Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., Zhao, L., Spisek, R., Kroemer, G., & Galluzzi, L. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03221-2 · Cited by 1,138
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 988
Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances
Xu, X., Pang, Y., & Fan, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02253-4 · Cited by 800
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
Metadata
- Authors
- Li, X.-Y., Moesta, A. K., Xiao, C., Nakamura, K., Casey, M., Zhang, H., Madore, J., Lepletier, A., Aguilera, A. R., Sundarrajan, A., Jacoberger-Foissac, C., Wong, C., dela Cruz, T., Welch, M., Lerner, A. G., Spatola, B. N., Soros, V. B., Corbin, J., Anderson, A. C., Effern, M., Hölzel, M., Robson, S. C., Johnston, R. L., Waddell, N., Smith, C., Bald, T., Geetha, N., Beers, C., Teng, M. W. L., & Smyth, M. J.
- Venue
- Cancer Discovery
- Published
- 2019-12-01
- Volume
- 9
- Issue
- 12
- Pages
- 1754-1773
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2986950076
- Cited by
- 264
- References
- 68
- FWCI
- 18.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.